Media Center

Press Releases

• Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (Als) Has Been Added To The Provincial Drug Plan In Manitoba

  TORONTO, ON, December 15, 2023 –...

  Read More
  December 15, 2023
• Mitsubishi Tanabe Pharma Canada Announces Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (Als) Now Eligible For Coverage Through Veteran Affairs Canada And Indigenous Services Canada

  TORONTO, ON, December 13, 2023 –...

  Read More
  December 13, 2023
• Mitsubishi Tanabe Pharma Canada Celebrates Five Years in Canada Supporting and Committed to People Living with ALS

  Mitsubishi Tanabe Pharma Canada (MTP-CA)...

  Read More
  November 29, 2023
• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plans in Prince Edward Island, Newfoundland and Labrador

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  November 7, 2023
• Canadian-Developed AI Technology Aims to Support Early Detection of ALS

  TORONTO, ON, September 20, 2023 –...

  Read More
  September 20, 2023
• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plans in Saskatchewan

  TORONTO, ON, September 1, 2023 –...

  Read More
  September 1, 2023
• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plans in New Brunswick and Nova Scotia

  TORONTO, ON, August 29, 2023 –...

  Read More
  August 29, 2023
• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in British Columbia

  TORONTO, ON, August 18, 2023 –...

  Read More
  August 18, 2023
• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Québec

  TORONTO, ON, August 16, 2023 –...

  Read More
  August 16, 2023
• Mitsubishi Tanabe Pharma Canada Announces Collaboration with the CNDR on First Canadian Real-World Evidence Study of RADICAVA® IV (edaravone) Survival Benefits in ALS

  TORONTO, ON, August 9, 2023 – Mitsubishi...

  Read More
  August 9, 2023
• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Alberta

  TORONTO, ON, August 3, 2023 – Mitsubishi...

  Read More
  August 3, 2023
• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Ontario

  TORONTO, ON, August 1, 2023 – Mitsubishi...

  Read More
  August 1, 2023
• Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with pan-Canadian Pharmaceutical Alliance for ^prRADICAVA^® Oral Suspension (Edaravone)

  TORONTO, ON, July 20, 2023 - Mitsubishi...

  Read More
  July 20, 2023
• Mitsubishi Tanabe Pharma Canada is Proud to Support a New HCP Directed Program: How to Break the News in ALS/MND

  Mitsubishi Tanabe Pharma Canada is Proud...

  Read More
  June 14, 2023
• Mitsubishi Tanabe Pharma Canada Announces New Leadership

  Mitsubishi Tanabe Pharma Canada Announces...

  Read More
  April 3, 2023
• Mitsubishi Tanabe Pharma Canada Receives Engagement Letter from pan-Canadian Pharmaceutical Alliance for ^prRADICAVA^® Oral Suspension

  TORONTO, Canada – March 30, 2023 –...

  Read More
  March 30, 2023
• Mitsubishi Tanabe Pharma Canada Announces ^prRADICAVA^® (Edaravone) Oral Suspension Is Now Available in Canada for the Treatment of Patients with ALS

  Mitsubishi Tanabe Pharma Canada, Inc....

  Read More
  February 10, 2023
• ^prRADICAVA^® (Edaravone) Oral Suspension Receives Positive Recommendation from CADTH for the Treatment of Patients with ALS

  Mitsubishi Tanabe Pharma Canada, Inc....

  Read More
  January 18, 2023
• ^prRADICAVA^® (Edaravone) Oral Suspension Receives Positive Recommendation from INESSS for the Treatment of Patients With ALS

  (MTPA) is pleased to announce a positive...

  Read More
  December 19, 2022
• Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of ^prRADICAVA^® (Edaravone) Oral Suspension for the Treatment of Patients with ALS

  Comprehensive clinical development program...

  Read More
  November 9, 2022
• Mitsubishi Tanabe Pharma Canada Announces Publication of Real-World Data for Radicava^® (Edaravone)

  TORONTO, ON August 15, 2022 – Mitsubishi...

  Read More
  August 15, 2022
• Health Canada Accepts SNDS Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS

  TORONTO, Canada - May 13, 2022 –...

  Read More
  May 13, 2022
• Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary

  TORONTO, November 23, 2021 - Mitsubishi...

  Read More
  November 23, 2021
• Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Is Now Available Through Newfoundland and Labrador Prescription Drug Program

  TORONTO, March 10, 2021 - Mitsubishi...

  Read More
  March 10, 2021
• MTP-CA Applauds the Release of Canada’s First ALS Management Guidelines

  Mitsubishi Tanabe Pharma Canada (MTP-CA)...

  Read More
  November 18, 2020
• Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) Now Eligible for Coverage Through Veterans Affairs Canada and Indigenous Services Canada

  TORONTO, September 21, 2020 - Mitsubishi...

  Read More
  September 21, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to British Columbia PharmaCare Formulary

  TORONTO, August 19, 2020 - Mitsubishi...

  Read More
  August 19, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Nova Scotia has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

  TORONTO, July 7, 2020 - Mitsubishi Tanabe...

  Read More
  July 7, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Manitoba has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

  TORONTO, June 30, 2020 - Mitsubishi Tanabe...

  Read More
  June 30, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Saskatchewan has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

  TORONTO, June 30, 2020 - Mitsubishi Tanabe...

  Read More
  June 30, 2020
• Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in New Brunswick

  TORONTO, June 18, 2020 - Mitsubishi Tanabe...

  Read More
  June 18, 2020
• Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta

  Mitsubishi Tanabe Pharma Canada, Inc....

  Read More
  June 1, 2020
• Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Ontario

  Mitsubishi Tanabe Pharma Canada, Inc....

  Read More
  May 28, 2020
• Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec

  Mitsubishi Tanabe Pharma Canada, Inc....

  Read More
  April 29, 2020
• Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA^® (edaravone)

  TORONTO, April 22, 2020 - Mitsubishi...

  Read More
  April 22, 2020
• MTP-CA’s Response to COVID-19

  Mitsubishi Tanabe Pharma Canada, Inc....

  Read More
  March 20, 2020
• Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA^® (edaravone) for Amyotrophic Lateral Sclerosis

  Mitsubishi Tanabe Pharma Canada, Inc....

  Read More
  November 5, 2019
• Update on Canadian Product Availability

  Mitsubishi Tanabe Pharma Canada (MTP-CA)...

  Read More
  October 23, 2019
• Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of RADICAVA™ (Edaravone) to Treat ALS

  TORONTO, October 4, 2018 -- Mitsubishi...

  Read More
  October 4, 2018
• New Country Manager Brings Significant Business Leadership and Healthcare Expertise to Mitsubishi Tanabe Pharma Canada, Inc.

  TORONTO, September 28, 2018 – Mitsubishi...

  Read More
  September 28, 2018

Load More